KURA ONCOLOGY, INC. Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions
KURA ONCOLOGY, INC. (KURA) reported Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions of $67.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions · last filed 2026-03-05
- KURA ONCOLOGY, INC. unrecognized tax benefits, increase resulting from prior period tax positions for fiscal 2024 was $67.00K, a 18.29% decline from fiscal 2023.
- KURA ONCOLOGY, INC. unrecognized tax benefits, increase resulting from prior period tax positions for fiscal 2023 was $82.00K, a 22.39% increase from fiscal 2022.
- KURA ONCOLOGY, INC. unrecognized tax benefits, increase resulting from prior period tax positions for fiscal 2022 was $67.00K.
- KURA ONCOLOGY, INC. unrecognized tax benefits, increase resulting from prior period tax positions for fiscal 2021 was $0.00.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2024-12-31 | $67.00K 10-K · filed 2026-03-05 |
| 2023-12-31 | $82.00K 10-K · filed 2026-03-05 |
| 2022-12-31 | $67.00K 10-K · filed 2025-02-28 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2017-12-31 | $42.00K 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |